Although treatment with mTOR inhibitors has shown positive results in preventing massive renal enlargement in a variety of polycystic kidney disease (PKD) animal models, clinical trials have not been able to show the same beneficial effect of mTOR inhibitors treatment in ADPKD patients4–8. The gene discussed is MTOR; the disease is autosomal dominant polycystic kidney disease.